Drug Profile
TCM 808FB
Latest Information Update: 30 Aug 2023
Price :
$50
*
At a glance
- Originator TCM Biotech International
- Class
- Mechanism of Action Immunoglobulin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatic fibrosis
Most Recent Events
- 30 Aug 2023 Discontinued - Preclinical for Hepatic fibrosis in Taiwan (unspecified route)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Hepatic-fibrosis in Taiwan
- 22 Feb 2016 Preclinical trials in Hepatic fibrosis in Taiwan (unspecified route)